UNSPSC 51434005: Vernakalant

This classification denotes a mixed ion channel blocker with the molecular formula C20H31NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9G468C8B13, chemically known as (3R)-1-[(1R,2R)-2-[2-(3,4-dimethoxyphenyl)ethoxy]cyclohexyl]pyrrolidin-3-ol but generally known as vernakalant, which bears US NIH Compound Identifier 9930049. Vernakalant most often comes in base and hydrochloride forms. European Medicines Agency schedules Vernakalant in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB30707.

UNSPSC 51434005 Vernakalant, a Commodity code, represents a single antiarrhythmic pharmaceutical product that state and local governments procure primarily through emergency medical services and public health programs. Recent state and local solicitations show vernakalant being acquired as part of broader Advanced Life Support medication portfolios rather than as a standalone line item, bundled with other injectable cardiovascular agents such as epinephrine, labetalol, adenosine, and diltiazem. Issuing bodies span municipal fire-rescue departments, state health agencies, and multistate cooperative purchasing alliances. The City of Tampa's Purchasing Department and the Texas Health and Human Services Commission represent the primary recent buyers, though vernakalant appears indirectly within the Minnesota Multistate Cooperative Purchasing Alliance's generic pharmaceuticals RFP framework rather than as an explicitly named product in current solicitations.

Activity under this code concentrates in Florida and Texas, with secondary cooperative purchasing participation in Minnesota and Oregon. The City of Tampa issued IFB No. 26P00188 on April 24, 2026, for Advanced Life Support Medications (due April 8, 2026) with an estimated contract value of $40,000, requiring suppliers to deliver medications to Tampa Fire Rescue within ten calendar days and maintain nine-month minimum expiration dates, with a one-year term plus optional renewals and 5 percent bid discounts for Small Local Business Enterprise participation. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, exploring direct-to-manufacturer prescription fulfillment strategies that would eventually support broader pharmaceutical sourcing, though vernakalant was not explicitly named. Minnesota's MMCAP issued RFP S1070000015802 (due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed to state and local facilities across multiple jurisdictions, with contract terms of two years and performance penalties for compliance violations. Recent opportunities emphasize cold-chain compliance, FDA manufacturing certifications, OSHA Safety Data Sheet documentation, and WCAG 2.2 accessibility standards for product information.